Role of ganaton in antiemetic therapy. New treatment capacities

The practical introduction of new effective drugs for the prevention and treatment of nausea and vomiting is one of the important constitu- ents of maintenance therapy in cancer patients, which helps maintain a good quality of life during drug treatment. This paper considers the main mechanisms of o...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Snegovoy, L. V. Manzyuk
Format: Article
Language:Russian
Published: ABV-press 2014-08-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/269
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839571004677947392
author A. V. Snegovoy
L. V. Manzyuk
author_facet A. V. Snegovoy
L. V. Manzyuk
author_sort A. V. Snegovoy
collection DOAJ
description The practical introduction of new effective drugs for the prevention and treatment of nausea and vomiting is one of the important constitu- ents of maintenance therapy in cancer patients, which helps maintain a good quality of life during drug treatment. This paper considers the main mechanisms of occurrence of nausea and vomiting and current recommendations for their prevention and gives the results of the authors’ studies evaluating the use of ganaton, a D2-receptor antagonist, alone and in combination with 5-HT3-receptor antagonists for the prevention and treatment of acute and delayed nausea and vomiting. The drug has shown a high efficacy and it is recommended for clinical application.
format Article
id doaj-art-d2aa9150d2f14bc6bb4da15cb5c4d0bc
institution Matheson Library
issn 1994-4098
1999-8627
language Russian
publishDate 2014-08-01
publisher ABV-press
record_format Article
series Опухоли женской репродуктивной системы
spelling doaj-art-d2aa9150d2f14bc6bb4da15cb5c4d0bc2025-08-04T14:33:38ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272014-08-0104495310.17650/1994-4098-2010-0-4-49-53285Role of ganaton in antiemetic therapy. New treatment capacitiesA. V. Snegovoy0L. V. Manzyuk1N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowThe practical introduction of new effective drugs for the prevention and treatment of nausea and vomiting is one of the important constitu- ents of maintenance therapy in cancer patients, which helps maintain a good quality of life during drug treatment. This paper considers the main mechanisms of occurrence of nausea and vomiting and current recommendations for their prevention and gives the results of the authors’ studies evaluating the use of ganaton, a D2-receptor antagonist, alone and in combination with 5-HT3-receptor antagonists for the prevention and treatment of acute and delayed nausea and vomiting. The drug has shown a high efficacy and it is recommended for clinical application.https://ojrs.abvpress.ru/ojrs/article/view/269antiemeticsnauseavomitingd2-antagonistsemetogenic complications5-ht3 and nk1-receptor antagonists
spellingShingle A. V. Snegovoy
L. V. Manzyuk
Role of ganaton in antiemetic therapy. New treatment capacities
Опухоли женской репродуктивной системы
antiemetics
nausea
vomiting
d2-antagonists
emetogenic complications
5-ht3 and nk1-receptor antagonists
title Role of ganaton in antiemetic therapy. New treatment capacities
title_full Role of ganaton in antiemetic therapy. New treatment capacities
title_fullStr Role of ganaton in antiemetic therapy. New treatment capacities
title_full_unstemmed Role of ganaton in antiemetic therapy. New treatment capacities
title_short Role of ganaton in antiemetic therapy. New treatment capacities
title_sort role of ganaton in antiemetic therapy new treatment capacities
topic antiemetics
nausea
vomiting
d2-antagonists
emetogenic complications
5-ht3 and nk1-receptor antagonists
url https://ojrs.abvpress.ru/ojrs/article/view/269
work_keys_str_mv AT avsnegovoy roleofganatoninantiemetictherapynewtreatmentcapacities
AT lvmanzyuk roleofganatoninantiemetictherapynewtreatmentcapacities